Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors

In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2...

Related Keywords

United States ,Haiyan ,Yunnan ,China ,Italy ,Sasayama ,Hyogo ,Japan ,Canada ,Spain ,Zhejiang ,Zaragoza ,Baja California ,Mexico ,Switzerland ,Toronto ,Ontario ,Sunnybrook ,Alberta ,Ivrea ,Piemonte ,American ,America ,Richard Jarvis ,Satoshi Sugimoto ,Marlena Abdinoor ,Sloan Simpson ,Michael Meo ,Isabella Zinck ,Imke Kappes ,Simron Singh ,Parag Mahanti ,Julie Masow ,Samir Shah ,Jeff Legos ,Jonathan Graham ,Nicole Zinsli Somm ,American Society Of Clinical Oncology ,University Of Toronto ,Sunnybrook Health Sciences Centre ,Global Head Of Oncology Development At Novartis ,Odette Cancer Centre ,Linkedin ,Exchange Commission ,Instagram ,Facebook ,Novartis ,Elsevier Inc ,Clinical Oncology ,Associate Professor ,Susan Leslie Clinic ,Neuroendocrine Tumours ,Global Head ,Oncology Development ,Radioligand Therapy ,Survival Outcomes ,Patients With Neuroendocrine Tumors ,Gastroenteropancreatic Neuroendocrine ,Patients With Grade ,Accessed January ,Full Prescribing ,Product Characteristics ,Clinical Radiation ,Markets ,